Fire ant venom could treat psoriasis, scientists claim
In trials on mice at the Emory University School of Medicine, Atlanta, the new cream was showed to reduce skin thickening and inflammation - both are typical features of the incurable disorder.
This study aimed to investigate the effect of black seed oil on imiquimod (IMQ) induced psoriasis‐like skin lesions. To this end, 30 male albino rats were divided into three groups: group I, control group; group II, psoriasis‐induced group receiving daily topical applications of IMQ cream (5%) on the shaved back skin for 10 consecutive days; and group III, black seed oil group receiving a daily topical dose of black seed oil 5 mg/kg body weight for 10 days after induction of psoriasis. Animals of all groups were sacrificed and specimens obtained from the skin of the central part of the back were processed for histologi...
For those with chronic plaque psoriasis, responses to tildrakizumab, an experimental interleukin-23 inhibitor, were upheld in two long-term extension studies, and FDA approval could be in the offing.Medscape Medical News
ConclusionsThe results of the present study indicate that the HLA‐DPB1*05:01 gene was associated with the geographical region of PV and the BTNL2 gene was significantly associated with family history and age of onset of PV. In conclusion, the HLA‐DPB1*05:01 and BTNL2 genes might be responsible for the complicacy of clinical features.
Abstract BackgroundApremilast is a novel oral phosphodiesterase‐4 inhibitor approved for psoriasis treatment. Randomized trials have documented its efficacy and safety, but data on real‐world patients are scarce. ObjectivesWe aim to characterize psoriasis patients treated with apremilast in a real‐world setting and calculate drug survival as an important measure of efficacy and compliance. MethodsAll psoriasis patients that received apremilast between April 1st 2015 and January 19th 2017 were evaluated every 4 weeks and we documented: age, weight, height, smoking status, family history of psoriasis, joint involvement...
Conclusions Psoriasis protects against a low MED. Although erythema and pruritus were more common in patients with a low MED, the differences were not significant.
More than 80 percent of patients receiving TREMFYA ™, including patients transitioned from Humira® to the anti-interleukin (IL)-23 monoclonal antibody, demonstrated PASI 90 and IGA 0/1 scores at week 100
AbstractPharmacogenetics is the study of variations in DNA sequence related to drug response. Moreover, the evolution of biotechnology and the sequencing of human DNA have allowed the creation of pharmacogenomics, a branch of genetics that analyzes human genes, the RNAs and proteins encoded by them, and the inter-and intra-individual variations in expression and function in relation to drug response. Pharmacogenetics and pharmacogenomics are being used to search for biomarkers that can predict response to systemic treatments, including those for moderate-to-severe psoriasis. Psoriasis is a chronic inflammatory disease with...
(MedPage Today) -- Risk calculated based on Body Surface Area measurement
Psoriasis is a skin condition that also affects the scalp in an estimated 50 percent of cases. Learn more about its treatment with medicinal shampoos.